Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Semaglutide for Weight Loss in Obese Pakistani Adults Without Type 2 Diabetes
NCT07513168Phase 4Recruiting
- Sponsor
- Asian Institute of Medical Sciences
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by Asian Institute of Medical Sciences. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07513168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513168.